Takeda Pharmaceutical Company Stocks List Ranked

Takeda Pharmaceutical Company ETFs
Recent Takeda Pharmaceutical Company News

Symbol	Grade	Name	% Change
XOMA	A	XOMA Corporation	-1.09
STTK	A	Shattuck Labs, Inc.	-1.21
ITCI	B	Intra-Cellular Therapies Inc.	-1.35
CRDF	B	Cardiff Oncology, Inc.	-4.55
AMGN	D	Amgen Inc.	-1.33
RXRX	D	Recursion Pharmaceuticals, Inc.	-1.26
OVID	F	Ovid Therapeutics Inc.	-5.08
LXRX	F	Lexicon Pharmaceuticals, Inc.	-3.75
GOSS	F	Gossamer Bio, Inc.	-5.41
TAK	F	Takeda Pharmaceutical Company Limited	-1.21

View As Page of Charts

Related ETFs - A few ETFs which own one or more of the above listed Takeda Pharmaceutical Company stocks.

Symbol	Grade	Name	Weight
BBH	D	Market Vectors Biotech ETF	14.82
IBBQ	D	Invesco Nasdaq Biotechnology ETF	9.76
IBB	D	iShares Nasdaq Biotechnology Index Fund	9.41
BIS	A	ProShares UltraShort Nasdaq Biotechnology	8.35
PBE	D	PowerShares Dynamic Biotech & Genome	7.92

View all Takeda Pharmaceutical Company ETFs...

Compare ETFs

Compare BBH to BIS Compare BIS to PBE Compare IBBQ to PBE

Takeda Pharmaceutical Company Stocks Recent News

Date	Stock	Title
Apr 25	CRDF	Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
Apr 25	TAK	Takeda said to have left industry trade group BIO
Apr 25	TAK	All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
Apr 25	TAK	TAK or CTLT: Which Is the Better Value Stock Right Now?
Apr 25	AMGN	20 Fastest Growing Health Tech Companies in the World
Apr 25	TAK	20 Fastest Growing Health Tech Companies in the World
Apr 25	RXRX	3 Millionaire-Maker Biotech Stocks
Apr 25	AMGN	Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
Apr 25	ITCI	Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Apr 25	XOMA	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
Apr 25	TAK	New Strong Buy Stocks for April 25th
Apr 25	TAK	Best Value Stocks to Buy for April 25th
Apr 25	TAK	Best Income Stocks to Buy for April 25th
Apr 24	ITCI	Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Apr 24	AMGN	Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Apr 24	XOMA	Actym Therapeutics Appoints Thomas Smart as CEO
Apr 23	TAK	Neurocrine succeeds in mid-stage trial for Takeda-partnered depression drug
Apr 23	XOMA	Day One wins FDA nod for brain cancer therapy, Ojemda
Apr 23	TAK	Takeda Pharmaceutical: A Long-Term Cash Cow
Apr 23	TAK	Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Takeda Pharmaceutical Company: The Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) [takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical and biopharmaceutical company. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 49,578 employees worldwide and achieved US $19.299 billion in revenue during the 2018 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo.
In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

More about Takeda Pharmaceutical Company

Browse All Tags